Office of Technology Management
Department of Pediatrics
The Office of Technology Management

Available Technologies

 


Back

Hyperplastic Vasculomyopathy Diagnostic

Market: In 2007 in the United States alone, it is estimated that direct and indirect costs of cardiovascular diseases is $481.8 billion. Each year hundreds of thousands of patients are diagnosed with vascular diseases such as myocardial infarction and stroke.

Competitors and Current Problems: A subset of individuals may have a genetic predisposition to vascular diseases. The ability to screen and identify individuals and their family members who are at risk for vascular disease will allow for preventative therapies (medical and surgical therapies), life-style modifications, and awareness of their susceptibility that will significantly reduce their risk of suffering a life-threatening or debilitating vascular event.

The Technology: The inventors have created novel genetic tests for diagnosing vascular disease and for assessing an individual’s risk of developing a vascular disease. Early detection of such mutations allows for the diagnosis and early treatment of such hyperplastic vasculomyopathy diseases as: stroke, myocardial infarction, aortic aneurysms and dissections, peripheral vascular disease, peripheral neuropathy, bicuspid aortic value, patent ductus arteriosus, cardiac arrhythmias, Sneddon’s syndrome, or Moyamoya disease, or a combination of any of those diseases. Validation studies are in progress.

UTHSC-H Ref. No.: 2004-0009
Lead Inventor: D. Milewicz
Patent Status: Pending; U.S. Publication No. 20080305498
License Available: world-wide; exclusive or non-exclusive

Download Summary (2004-0009)